ea0029p1003 | Growth hormone IGF axis - basic | ICEECE2012
Jen J.
, LaBadie R.
, Liang Y.
, Crownover P.
, Gao X.
, Hey-Hadavi J.
Introduction: Pegvisomant is indicated for acromegaly. Doses >20 mg are not commercially available, although daily doses up to 30 mg are approved.Objectives: 1. To estimate the relative bioavailability (relBA) of single-dose pegvisomant s.c. administrations, one injection of 30 mg/ml (1×30) vs two injections of 15 mg/ml (2×15), and 2. To evaluate their pharmacokinetics (PK), safety and tolerability.Methods: This was a...